XML 35 R32.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Collaborative and Other Agreements - Additional Information (Details) € in Millions |  | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2015 USD ($) | Sep. 30, 2015 USD ($) | Sep. 30, 2014 USD ($) | Sep. 30, 2015 USD ($) | Sep. 30, 2015 EUR (€) | Sep. 30, 2014 USD ($) | Dec. 31, 2014 USD ($) | [1]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License and collaborative fees |  | $ 645,000 | $ 2,450,000 | $ 1,852,000 |  | $ 4,615,000 |
Deferred revenue – current | $ 39,345,000 | 39,345,000 |  | 39,345,000 |  |  | $ 1,089,000
Collaborative Arrangement | Novartis [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment received |  |  |  | 37,000,000 |  |  |
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones |  |  |  | 480,000,000 |  |  |
Milestone received under the collaboration agreement | 0 |  |  |  |  |  |
Upfront payment included in trade and other receivables and deferred revenue current | 37,000,000 | 37,000,000 |  | 37,000,000 |  |  |
Collaborative Arrangement | Servier [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Future initial research and development expenses to be funded by counterparty |  |  |  | 50,000,000 |  |  |
License and collaborative fees |  | 200,000 | $ 600,000 | 1,100,000 |  | $ 2,600,000 |
Eligible milestone payments receivable | € |  |  |  |  | € 356.5 |  |
Eligible milestone payments receivable under specific rights not met | € |  |  |  |  | 633.8 |  |
Eligible milestone payments receivable, after amendment | € |  |  |  |  | 341.5 |  |
Eligible milestone payments receivable under specific rights not met, after amendment | € |  |  |  |  | € 618.8 |  |
Deferred revenue – current | $ 1,400,000 | $ 1,400,000 |  | $ 1,400,000 |  |  |
Collaborative Arrangement | Symplmed Pharmaceuticals [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Royalties receivable percentage, minimum |  |  |  | 3.00% | 3.00% |  |
Royalties receivable percentage, maximum |  |  |  | 10.00% | 10.00% |  |
[1] | The condensed consolidated balance sheet as of December 31, 2014 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the eligible milestone payments receivable, if the company re-acquired cardiovascular and/or diabetes rights for use in the United States. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents eligible milestone payments receivable after amendments, if the company re-acquired cardiovascular and/or diabetes rights for use in the United States. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableAfterAmendments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents eligible milestone payments receivable, if the company did not re-acquire those rights. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUnderSpecificRightsNotMet
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents Eligible milestone payments receivable, if the company did not re-acquire those rights after amendment. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUnderSpecificRightsNotMetAfterAmendment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible milestone payments receivable upon achievement of development regulatory and commercial milestones. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of future initial clinical research and development expenses that will be funded by the counterparty. + References No definition available. + Details
Name: | xoma_FutureInitialResearchAndDevelopmentExpensesToBeFundedByCounterparty
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. + References No definition available. + Details
Name: | xoma_MilestoneReceivedUnderCollaborationAgreement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Proceeds from upfront payment. + References No definition available. + Details
Name: | xoma_ProceedsFromUpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Pertains to maximum royalty receivable from potential product sale. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageMaximum
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pertains to minimum royalty receivable from potential product sale. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageMinimum
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment included in trade and other receivables and deferred revenue current. + References No definition available. + Details
Name: | xoma_UpfrontPaymentIncludedInTradeAndOtherReceivablesAndDeferredRevenueCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xoma_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xoma_ServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xoma_SymplmedPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |